EGFR and esophageal squamous cell carcinoma: Aiming to improve efficacy, clinical trials in ESCC have investigated EGFR inhibitors when combined with standard cytotoxic chemotherapies, chemoradiotherapy or radiotherapy alone [14], with improvements in progression-free survival [15] and overall survival (OS) [16].